IP Library Granted Patent US 9,505,742
Granted Patent B2
US 9,505,742 · App. 14/947,730 · Granted Nov 29, 2016

3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds

Inventors: Johannes Aebi (Binningen, CH); Kurt Amrein (Itingen, CH); Wenming Chen (Shanghai, CN); Benoit Hornsperger (Altkirch, FR); Bernd Kuhn (Reinach BL, CH); Dongbo Li (Shanghai, CN); Yongfu Liu (Shanghai, CN); Hans P. Maerki (Basel, CH); Rainer E. Martin (Basel, CH); Alexander Mayweg (Basel, CH); Xuefei Tan (Shanghai, CN); Lisha Wang (Basel, CH); Jun Wu (Shanghai, CN); Mingwei Zhou (Shanghai, CN)
Assignee: Hoffmann-La Roche Inc.
C07D401/14C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,505,742
App. No.
14/947,730
Granted
Nov 29, 2016
Kind
B2
Abstract

The invention provides novel compounds having the general formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , A, B, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.

Claims (99)

1. A Compound of formula (I)

wherein

R 1 , R 2 , R 3 and R 4 are independently selected from H, alkyl and cycloalkyl;

R 5 , R 6 , R 7 and R 9 are independently selected from H, alkyl, halogen and hydroxy;

R 8 and R 11 together form —CH 2 —CH 2 —;

R 10 is H or R 10 and R 11 together form —(CH 2 ) w —;

A is —C(O)— or —S(O) 2 —;

B is —C— or —N—;

R 12 is alkyl, cycloalkyl or substituted heteroaryl, wherein substituted heteroaryl is substituted with one to three substituent independently selected from H, alkyl, cycloalkyl, hydroxy, alkoxy, cyano and halogen;

R 13 is halogen, cyano, alkoxy or haloalkoxy;

R 14 is H, alkyl or halogen;

m, n and p are independently selected from zero and 1;

w is 1, 2 or 3;

with the proviso that 2-[5-(1-acetyl-pyrrolidin-3-yl)-pyridin-3-yl]-5-chloro-3,3-dimethyl-2,3-dihydro-isoindol-1-one and 2-(1′-acetyl-1′,2′,3′,4′,5′,6′-hexahydro-[3,4′]bipyridinyl-5-yl)-5-chloro-3,3-dimethyl-2,3-dihydro-isoindol-1-one are excluded;

or a and pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein R 1 and R 2 are independently selected from H and alkyl.

3. The compound according to claim 1 , wherein R 1 and R 2 are alkyl.

4. The compound according to claim 1 , wherein R 1 and R 2 are methyl.

5. The compound according to claim 1 , wherein m and n is zero.

6. The compound according to claim 1 , wherein p is 1.

7. The compound according to claim 1 wherein R 7 is H or halogen.

8. The compound according to claim 1 , wherein R 7 is H.

9. The compound according to claim 1 , wherein R 9 is H.

10. The compound according to claim 1 , wherein R 10 is H.

11. The compound according to claim 1 , wherein A is —S(O) 2 —.

12. The compound according to claim 1 , wherein R 12 is alkyl or cycloalkyl.

13. The compound according to claim 1 , wherein R 12 is alkyl.

14. The compound according to claim 1 , wherein R 12 is ethyl, propyl, isopropyl.

15. The compound according to claim 1 , wherein R 12 is ethyl.

16. The compound according to claim 1 , wherein R 13 is chloro.

17. The compound according to claim 1 , wherein R 14 is H.

18. The compound according to claim 1 , wherein R 1 and R 2 are methyl, R 7 , R 9 , R 10 and R 14 are H, R 13 is chloro, A is —S(O) 2 —, m and n are zero, p is 1 and R 12 is alkyl or cycloalkyl.

19. The compound according to claim 1 , wherein R 1 and R 2 are methyl, R 7 , R 9 , R 10 and R 14 are H, R 13 is chloro, A is —S(O) 2 —, m and n are zero, p is 1 and R 12 is alkyl.

20. The compound according to claim 1 , selected from

5-Chloro-3,3-dimethyl-2-[5-(1-propanoylpiperidin-4-yl)pyridin-3-yl]isoindol-1-one;

5-Chloro-2-[5-(1-ethylsulfonylpiperidin-4-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-(1-methylsulfonylpiperidin-4-yl)pyridin-3-yl]isoindol-1-one;

5-Chloro-2-[5-(1-ethylsulfonylpiperidin-3-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-[(3R or 3S)-1-methylsulfonylpiperidin-3-yl]pyridin-3-yl]isoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-[(3S or 3R)-1-methylsulfonylpiperidin-3-yl]pyridin-3-yl]isoindol-1-one;

5-Chloro-2-[5-(1-ethylsulfonylpyrrolidin-3-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-[(3R or 3S)-1-propylsulfonylpyrrolidin-3-yl]pyridin-3-yl]isoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-[(3S or 3R)-1-propylsulfonylpyrrolidin-3-yl]pyridin-3-yl]isoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-[(3R or 3S)-1-propan-2-ylsulfonylpyrrolidin-3-yl]pyridin-3-yl]isoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-[(3S or 3R)-1-propan-2-ylsulfonylpyrrolidin-3-yl]pyridin-3-yl]isoindol-1-one;

5-Chloro-2-[5-[(3R or 3S)-1-cyclopropylsulfonylpyrrolidin-3-yl]pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-2-[5-[(3S or 3R)-1-cyclopropylsulfonylpyrrolidin-3-yl]pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-2-[5-(3-fluoro-1-propan-2-ylsulfonylpyrrolidin-3-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-(1-propylsulfonylpiperidin-4-yl)pyridin-3-yl]isoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-(1-propan-2-ylsulfonylpiperidin-4-yl)pyridin-3-yl]isoindol-1-one;

5-Chloro-2-[5-(1-cyclopropylsulfonylpiperidin-4-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-[1-(4-methylpyridine-3-carbonyl)piperidin-4-yl]pyridin-3-yl]isoindol-1-one;

5-Chloro-2-[5-[1-(3-chloropyridine-4-carbonyl)piperidin-4-yl]pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-2-[5-[1-(3-chloropyridine-2-carbonyl)piperidin-4-yl]pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-2-[5-(1-ethylsulfonylpiperidin-4-yl)pyridin-3-yl]-3H-isoindol-1-one;

5-Chloro-2-[5-(1-propan-2-ylsulfonylpiperidin-4-yl)pyridin-3-yl]-3H-isoindol-1-one;

5-Chloro-2-[5-[1-(4-methylpyridine-3-carbonyl)piperidin-4-yl]pyridin-3-yl]-3H-isoindol-1-one;

(3R or 3S)-5-Chloro-2-[5-(1-ethylsulfonylpiperidin-4-yl)pyridin-3-yl]-3-methyl-3H-isoindol-1-one;

(3S or 3R)-5-Chloro-2-[5-(1-ethylsulfonylpiperidin-4-yl)pyridin-3-yl]-3-methyl-3H-isoindol-1-one;

(3R or 3S)-5-Chloro-3-methyl-2-[5-(1-propan-2-ylsulfonylpiperidin-4-yl)pyridin-3-yl]-3H-isoindol-1-one;

(3S or 3R)-5-Chloro-3-methyl-2-[5-(1-propan-2-ylsulfonylpiperidin-4-yl)pyridin-3-yl]-3H-isoindol-1-one;

(3R or 3S)-5-Chloro-3-methyl-2-[5-[1-(4-methylpyridine-3-carbonyl)piperidin-4-yl]pyridin-3-yl]-3H-isoindol-1-one;

(3S or 3R)-5-Chloro-3-methyl-2-[5-[1-(4-methylpyridine-3-carbonyl)piperidin-4-yl]pyridin-3-yl]-3H-isoindol-1-one;

5-Chloro-2-[5-(1-ethylsulfonyl-4-fluoropiperidin-4-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-2-[5-(4-fluoro-1-propan-2-ylsulfonylpiperidin-4-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-2-[5-(1-ethylsulfonylazetidin-3-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

2-[5-(1-Acetylazetidin-3-yl)pyridin-3-yl]-5-chloro-3,3-dimethylisoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-(1-propylsulfonylazetidin-3-yl)pyridin-3-yl]isoindol-1-one;

5-Chloro-2-[5-(1-cyclopropylsulfonylazetidin-3-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-[1-(4-methylpyridine-3-carbonyl)azetidin-3-yl]pyridin-3-yl]isoindol-1-one;

5-Chloro-2-[5-(4-fluoro-1-propylsulfonyl-4-piperidyl)-3-pyridyl]-3,3-dimethyl-isoindolin-1-one;

5-Chloro-2-[5-(1-cyclopropylsulfonyl-4-fluoro-4-piperidyl)-3-pyridyl]-3,3-dimethyl-isoindolin-1-one;

2-[5-(4-Fluoro-1-isopropylsulfonyl-4-piperidyl)-3-pyridyl]-3,3-dimethyl-1-oxo-isoindoline-5-carbonitrile;

6-[5-(1-Ethylsulfonyl-4-fluoro-4-piperidyl)-3-pyridyl]-2-methoxy-7,7-dimethyl-pyrrolo[3,4-b]pyridin-5-one;

6-[5-[4-Fluoro-1-(1-methylpyrazole-4-carbonyl)-4-piperidyl]-3-pyridyl]-2-methoxy-7,7-dimethyl-pyrrolo[3,4-b]pyridin-5-one;

6-[5-(4-Fluoro-1-isopropylsulfonyl-4-piperidyl)-3-pyridyl]-2-methoxy-7,7-dimethyl-pyrrolo[3,4-b]pyridin-5-one;

6-[5-(4-Fluoro-1-propylsulfonyl-4-piperidyl)-3-pyridyl]-2-methoxy-7,7-dimethyl-pyrrolo[3,4-b]pyridin-5-one;

6-[5-[4-Fluoro-1-(1-methylimidazole-2-carbonyl)-4-piperidyl]-3-pyridyl]-2-methoxy-7,7-dimethyl-pyrrolo[3,4-b]pyridin-5-one;

6-[5-(1-Cyclopropylsulfonyl-4-fluoro-4-piperidyl)-3-pyridyl]-2-methoxy-7,7-dimethyl-pyrrolo[3,4-b]pyridin-5-one;

6-[5-(1-Ethylsulfonyl-4-piperidyl)-3-pyridyl]-2-methoxy-7,7-dimethyl-pyrrolo[3,4-b]pyridin-5-one;

2-Methoxy-7,7-dimethyl-6-[5-[1-(1-methylpyrazole-4-carbonyl)-4-piperidyl]-3-pyridyl]pyrrolo[3,4-b]pyridin-5-one;

2-Methoxy-7,7-dimethyl-6-[5-[1-(2-methylpyrazole-3-carbonyl)-4-piperidyl]-3-pyridyl]pyrrolo[3,4-b]pyridin-5-one;

2-Methoxy-7,7-dimethyl-6-[5-[1-(4-methylpyridine-3-carbonyl)-4-piperidyl]-3-pyridyl]pyrrolo[3,4-b]pyridin-5-one;

and pharmaceutically acceptable salts thereof.

21. The compound according to claim 1 , selected from

5-Chloro-2-[5-(1-ethylsulfonylpiperidin-4-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-(1-propylsulfonylpiperidin-4-yl)pyridin-3-yl]isoindol-1-one;

5-Chloro-3,3-dimethyl-2-[5-(1-propan-2-ylsulfonylpiperidin-4-yl)pyridin-3-yl]isoindol-1-one;

5-Chloro-2-[5-(1-cyclopropylsulfonylpiperidin-4-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

(3R or 3S)-5-Chloro-2-[5-(1-ethylsulfonylpiperidin-4-yl)pyridin-3-yl]-3-methyl-3H-isoindol-1-one

5-Chloro-2-[5-(1-cyclopropylsulfonyl-4-fluoro-4-piperidyl)-3-pyridyl]-3,3-dimethyl-isoindolin-1-one;

2-[5-(4-Fluoro-1-isopropylsulfonyl-4-piperidyl)-3-pyridyl]-3,3-dimethyl-1-oxo-isoindoline-5-carbonitrile;

and pharmaceutically acceptable salts thereof.

22. The compound according to claim 1 , wherein the compound is

5-Chloro-2-[5-(1-ethylsulfonylpiperidin-4-yl)pyridin-3-yl]-3,3-dimethylisoindol-1-one;

and pharmaceutically acceptable salts thereof.

23. A process to prepare a compound according to claim 1 comprising the reaction of a compound of formula (II) in the presence of a compound of formula (III);

wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , A, m, n and p are as defined in claim 1 and X is halogen or triflate.

24. A pharmaceutical composition comprising a compound according to claim 1 and a therapeutically inert carrier.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2025
From: HOFFMANN-LA ROCHE INC.
To: CINCOR PHARMA, INC.
Reel/Frame 071166/0614 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2016
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 040116/0906 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2016
From: TAN, XUEFEI; LIU, YONGFU; WANG, LISHA; ZHOU, MINGWEI; LI, DONGBO; CHEN, WENMING; WU, JUN; MAYWEG, ALEXANDER; MAERKI, HANS P.; AMREIN, KURT; HORNSPERGER, BENOIT; KUHN, BERND; MARTIN, RAINER E.; AEBI, JOHANNES
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 040473/0646 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2016
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 038065/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2016
From: TAN, XUEFEI; LIU, YONGFU; ZHOU, MINGWEI; LI, DONGBO; CHEN, WENMING; WU, JUN; WANG, LISHA; MAYWEG, ALEXANDER; MAERKI, HANS P.; AMREIN, KURT; AEBI, JOHANNES; HORNSPERGER, BENOIT; KUHN, BERND; MARTIN, RAINER E.
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 038205/0296 →
Priority Claims (1)
CN PCT/CN2013/076276 · May 27, 2013 · national
Continuity (2)
Continuation PCTEP2014060784 · May 26, 2014
Related Publication 20160075686A1 · Mar 17, 2016